Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

US10471061B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• University of Utah Research Foundation · US

Inventors

• Matthew B. Boxer · Point of Rocks, US
• Martin J. Walsh · Carmel, US
• Li Liu · Doylestown, US
• Cordelle D. Tanega · Rockville, US
• Min-Jui Richard Shen · Boyds, US
• Kent Lai · Salt Lake City, US
• Manshu Tang · Salt Lake City, US
• Douglas S. Auld · Waltham, US

Key dates

• Filing date: Oct 5, 2018
• Grant date: Nov 12, 2019
• Expiry date: Oct 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are inhibitors of human galactokinase of formula (I) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).